Treating mouse models of Alzheimer's disease with an antibody that blocks PD-1, the same molecule targeted by Merck & Co Inc.'s Keytruda (pembrolizumab), helped them clear amyloid plaque and improved their cognitive performance, scientists from the Israeli Weizmann Institute of Science reported in the Jan. 18, 2016, issue of Nature Medicine.